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We reported that connexin genes, a member of gap
junction, act as a tumor suppressor with certain specific- Calcium on trial:
ity [2, 3]. That is, connexin preferentially exerts a tumor-
suppressive effect on the tumor different from normal Beyond a reasonable doubt?
progenitor cells in which the particular connexin gene is
naturally expressed. Thus, to clarify the exact role of the
To the Editor: The interesting paper by Chertow et alconnexin gene as a tumor-suppressor gene in each tissue,
[1] brings up five interesting points. First, their studyit is necessary to determine the connexin subtype spe-
does not discuss previous studies with electron beamcifically expressed in the progenitor cell of each tumor.
tomography (EBT) in dialysis patients [2, 3], which dem-Recently, we showed that connexin 32 is specifically
onstrate different progression rates associated with lipiddown-regulated in renal cell carcinoma from mainte-
status [3], like that in the general population (Fig. 1),nance hemodialysis patients and several renal carcinoma
cells established from the maintenance hemodialysi pa- and show a lack of any relationship between serum cal-
tients [4]. On the other hand, we confirmed that human cium and EBT score in the general population [4].
renal proximal tubular cell (a progenitor cell of renal Second, the patients cited in Tables 3 and 4 of their
cell carcinoma) and noncancerous regions of kidneys study are not the same. Because Chertow et al excluded
from maintenance hemodialysis patients have the ex- patients with an EBT score30, evidence must be gath-
pression of connexin 32. Furthermore, we found that the ered to establish that the characteristics of the overall
recovery of the expression of connexin 32 in the renal population (92 who were given sevelamer and 94 who
carcinoma cells reduced some malignant phenotypes of were given calcium) are the same of the only 66 and 75
the cells. These results suggest that connexin 32 acts as patients, respectively, in whom the EBT scores have
a tumor suppressor against renal cell carcinoma from been evaluated.
mainenance hemodialysis patients. Overall, maintaining Third, those patients who progress rapidly have signifi-
the expression of connexin 32 during the development cantly higher mean serum calcium and rate of hypercalce-
of renal cell carcinoma in maintenance hemodialysis pa- mia (16% calcium subjects versus 5% sevelamer subjects)
tients may be a preventive procedure for the occurrence and at least one hypercalcemic episode (results, 43% and
of renal cell carcinoma.
17%, respectively). However, multivariate analysis evalu-
ating the role of hypercalcemia and hypercalcemic epi-Tomohiro Yano, Fumio Ito, Haruna Satoh,
Kiyokau Hagiwara, Hayakazu Nakazawa, sodes in the progression of calcification was lacking.
Hiroshi Toma, and Hiroshi Yamasaki Fourth, because only a minority of patients without
Tokyo and Hyogo, Japan
coronary or aortic calcification progressed (five of 25 and
five of 32 patients), how many non-progressors belonged
to the sevelamer- or calcium-treated subgroups? Because 2003 by the International Society of Nephrology
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